Intra-articular zoledronic acid in a rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect

  • B. Murat Cınar
  • Gurkan Ozkoc
  • Filiz Bolat
  • Oguz Karaeminogullari
  • Nurzen Sezgin
  • Reha N. Tandogan
Experimental Study

Abstract

Purpose

The aim of this experimental study was to evaluate the effect of intra-articular application of zoledronic acid (ZA) on joint cartilage and synovial tissue following induction of knee osteoarthritis (OA) in a rat model.

Methods

An OA model was created by anterior cruciate ligament transection (ACLT) in the right knees of 48 adult Wistar albino rats. The rats were randomized into a study and control groups, each including 24 rats, and 10 μg of ZA was injected in 0.1 ml of sterile saline to 24 animals in the study group on the first day to operation and was repeated weekly until the rats were killed. The same volume of sterile saline was injected with the same schedule to the control group. Eight rats from both the study and control groups were killed, each time, on the 4th day, the 3rd week, and the 6th week after the operation. The groups were compared based on the histological scores of synovitis and cartilage destruction and the evaluation of serum markers.

Results

Histological score indicates progression of synovitis was significantly less in the study group (p = 0.047). There was significant increase in the mean Mankin cartilage damage score in the control group (p = 0.021), while no significant change was found in the study group. When the two groups were compared over time, no statistically significant difference was detected in total histological scores, although there was a 47 % less incidence of cartilage tissue damage in the study group and better cartilage structure and tide mark integrity scores were also detected in the study group (p = 0.017 and p = 0.021, respectively).

Conclusion

Intra- articular zoledronic acid may suppress synovial inflammation. Furthermore, Zoledronic Acid does not reduce cartilage degeneration in early osteoarthritis models, but may provide some chondroprotective effect in ACLT- induced knee osteoarthritis model in rats.

Keywords

Zoledronic acid Osteoarthritis Intra-articular 

References

  1. 1.
    Andreollo NA, Santos EF, Araujo MR, Lopes LR (2012) Rat’s age versus human’s age: what is the relationship? ABCD Arg Bras Cir Dig 25(1):49–51CrossRefGoogle Scholar
  2. 2.
    Bendele AM (2001) Animal models of osteoarthritis. J Musculoskel Neuron Interact 1(4):363–376Google Scholar
  3. 3.
    Biswal S, Hastie T, Andriacchi TP, Bergman GA, Dillingman MF, Lang P (2002) Risk factors for progressive cartilage loss in the knee: a longitudinal magnetic resonance imaging study in forty-three patients. Arthritis Rheum 46(11):2884–2892CrossRefPubMedGoogle Scholar
  4. 4.
    Bobinac D, Spanjol J, Zoricic S, Maric I (2003) Changes in articular cartilage and subchondral bone histomorphometry in osteoarthritic knee joints in humans. Bone 32:284–290CrossRefPubMedGoogle Scholar
  5. 5.
    Carbone LD, Nevitt MC, Wildy K, Barrow KD et al (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50(11):3516–3525CrossRefPubMedGoogle Scholar
  6. 6.
    Ceponis A, Waris E, Mönkkönen J, Laasonen L, Hyttinen M (2001) Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosion and proteoglycan loss in established antigen- induced arthritis in rabbits. Arthritis Rheum 44(8):1908–1916CrossRefPubMedGoogle Scholar
  7. 7.
    Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048–2056CrossRefPubMedGoogle Scholar
  8. 8.
    Doschak MR, Wohl GR, Hanley DA, Bray RC, Zernicke RF (2004) Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J Orthop Res 22:942–948CrossRefPubMedGoogle Scholar
  9. 9.
    Garnero P, Delmas PD (2003) Biomarkers in osteoarthritis. Curr Opin Rheumatol 15:641–646CrossRefPubMedGoogle Scholar
  10. 10.
    Goldring MB (2000) The role of the chondrocyte in osteoarthritis. Arthritis Rheum 43:1916–1926CrossRefPubMedGoogle Scholar
  11. 11.
    Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S (2003) Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 30:474–479PubMedGoogle Scholar
  12. 12.
    Hayami T, Pickarski M, Wesolowski GA, Mclane J, Bone A, Destefano J, Rodan GA, Duong LT (2004) The role of subchondral bone remodeling in osteoarthritis. Arthritis Rheum 50(4):1193–1206CrossRefPubMedGoogle Scholar
  13. 13.
    Hayami T, Pickarski M, Ya Zhuo, Wesolowski GA, Rodan GA, Le Duong T (2006) Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38:234–243CrossRefPubMedGoogle Scholar
  14. 14.
    Helmark IC, Mikkelsen UR, Krogsgaard MR, Belhage B, Petersen MCH, Langberg H, Kjaer M (2010) Early osteoarthritis and microdialysis: a novel in vivo approach for measurements of biochemical markers in the perisynovium and intraarticularly. Knee Surg Sports Traumatol Arthrosc 18:1617–1623CrossRefPubMedGoogle Scholar
  15. 15.
    Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D et al (2011) Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartlil 19(5):515–542CrossRefGoogle Scholar
  16. 16.
    Larsson E, Müssener A, Heinegard D, Klareskog L, Saxne T (1997) Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. Br J Rheumatol 36:1258–1261CrossRefPubMedGoogle Scholar
  17. 17.
    Liu W, Burton-Wurster N, Glant TT et al (2003) Spontaneous and experimental osteoarthritis in dog: similarities and differences in proteoglycan levels. J Orthop Res 21(4):730–737CrossRefPubMedGoogle Scholar
  18. 18.
    Lohmander LS (2000) What can we do about osteoarthritis? Arthritis Res 2:95–100CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Mankin HJ, Dorfman H, Lippiello L, Zarins A (1971) Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg [Am] 53:523–537Google Scholar
  20. 20.
    Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, Zhao H, Iwamoto Y (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30:1280–1290PubMedGoogle Scholar
  21. 21.
    McDaniel WJ, Dameron TB (1983) The untreated anterior cruciate ligament rupture. Clin Orthop Relat Res 172:158–163PubMedGoogle Scholar
  22. 22.
    Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Canser 104(1):83–93Google Scholar
  23. 23.
    Moskowitz RW (1992) Experimental models of osteoarthritis. In: Moskowitz RW (ed) osteoarthritis, 2nd edn. Saunders, Philadelphia, pp 213–232Google Scholar
  24. 24.
    Niedhart M, Hauser N, Paulsson M, Dicesare PE, Michel BA, Hauselmann HJ (1997) Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. J Rheumatol [Br] 36:1151–1160CrossRefGoogle Scholar
  25. 25.
    Otto S, Sotlar K, Ehrenfeld M, Pautke C (2011) Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: a case report. J Med Case Rep 23(5):477CrossRefGoogle Scholar
  26. 26.
    Pelletier JP, Mineau F, Faure MP, Martel-Pelletier J (1990) Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 33(10):1466–1476CrossRefPubMedGoogle Scholar
  27. 27.
    Podworny NV, Kandel RA, Renlund RC, Grynpas MD (1999) Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 26:1972–1982PubMedGoogle Scholar
  28. 28.
    Radin EL, Rose RM (1986) Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 213:34–40PubMedGoogle Scholar
  29. 29.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661CrossRefPubMedGoogle Scholar
  30. 30.
    Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956–963CrossRefPubMedGoogle Scholar
  31. 31.
    Rossini M, Viapiana O, Ramonda R, Bianchi G, Olivieri I et al (2009) Intra-articular clodronate for the treatment of knee osteoarthritis: doe ranging study versus hyalunaric acid. Rheumatology 48:773–778CrossRefPubMedGoogle Scholar
  32. 32.
    Rutgers M, van Pelt MJ, Dhert WJ, Creemers LB, Saris DB (2010) Evaluation of histological scoring systems for tissue-engineered, repaired and osteoarthritic cartilage. Osteoarthr Cartlil 18(1):12–23CrossRefGoogle Scholar
  33. 33.
    Strassle BW, Mark L, Leventhal L, Piesla MJ, Jian LI, Kennedy JD, Glasson SS, Whiteside GT (2010) Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthr Cartlil 18:1319–1328CrossRefGoogle Scholar
  34. 34.
    Tandoğan RN, Taşer O, Kayaalp A, Taşkıran E, Pınar H, Alparslan B, Alturfan A (2004) Analysis of meniscal and chondral lesions accompanying anterior cruciate ligament tears: relationship with age, time from injury, and level of sport. Knee Surg Sports Traumatol Arthrosc 12:262–270CrossRefPubMedGoogle Scholar
  35. 35.
    Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Valleala H, Sorsa T (1997) Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int 61:59–61CrossRefPubMedGoogle Scholar
  36. 36.
    Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS (2002) Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61:925–928CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • B. Murat Cınar
    • 1
  • Gurkan Ozkoc
    • 1
  • Filiz Bolat
    • 2
  • Oguz Karaeminogullari
    • 3
  • Nurzen Sezgin
    • 4
  • Reha N. Tandogan
    • 5
  1. 1.Department of Orthopedics and Traumatology, Adana Research and Clinic CenterBaskent University School of MedicineYuregir/AdanaTurkey
  2. 2.Department of PathologyBaskent University School of MedicineAdanaTurkey
  3. 3.Department of Orthopedics and TraumatologyBayındır HospitalAnkaraTurkey
  4. 4.Department of BiochemistiryBaskent University School of MedicineAdanaTurkey
  5. 5.Department of Orthopedics and TraumatologyÇankaya HospitalAdanaTurkey

Personalised recommendations